Eton Pharma rises after US FDA accepts application for hormone disorder drug
View all comments(0)
Shares of drugmaker Eton Pharmaceuticals ETON.O rise 3.5% to $14.90 premarket
Co says the US FDA has accepted its application for potential approval of its drug candidate ET-600
If approved, ET-600 is expected to be the only oral liquid option on the market for central diabetes insipidius, ETON says
Central diabetes insipidius is a condition where the body doesn't produce enough vasopressin, a hormone that regulates water balance by signaling kidneys to conserve water
The FDA will give its decision on ET-600 on or before February 26, 2026
Up to last close, stock had risen 8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.